The PRACTICAL CONSORTIUM (in addition to those named in the author list)

Information of the consortium can be found at http://practical.icr.ac.uk/

Additional members from the consortium are:

Zsofia Kote-Jarai1, UKGPCS collaborators2, Artitaya Lophatananon3, Alison M. Dunning4, Maya Ghoussaini5, Fredrick R. Schumacher6,7, Loic Le Marchand8, Xin Sheng9, Xin Gao10, Bernd Holleczek11, Ben Schöttker10, Johanna Schleutker12,13, Teuvo L. J. Tammela14, Csilla Sipeky12, Anssi Auvinen15, Jyotsna Batra16, 17, APCB (Australian Prostate Cancer BioResource)17, 18, Suzanne Chambers19, 20, Lisa Horvath21,22, Leire Moya17,23, Gail P. Risbridger24, 25, Wayne Tilley26, Judith A. Clements17, 23, David E. Neal27, 28, 29, Jenny L. Donovan30, Freddie C. Hamdy31, 32, Richard M. Martin30, 33, 34, Sune F. Nielsen35, 36, Stig E. Bojesen35, 36, Peter Iversen37, Martin Andreas Røder37, Henrik Grönberg38, Fredrik Wiklund38, Graham G. Giles39, 40, 41, Melissa C. Southey39, 41, 42, Robert J. MacInnis39, 40, Roger L. Milne39, 40, 41, Ruth C. Travis43, Tim J. Key43, William J. Blot44, 45, Wei Zheng44, Janet L. Stanford46, 47, Elaine A. Ostrander48, Milan S. Geybels46, Børge G. Nordestgaard35, 36, Adam S. Kibel49, Bettina F. Drake50, Markus Aly38, 51, 52, Cezary Cybulski53, Dominika Wokolorczyk53, Jan Lubinski53, Kay-Tee Khaw54, Christiane Maier55, Manuel Luedeke55, Thomas Schnoeller56, Stephen N. Thibodeau57, Shannon K. McDonnell58, Daniel J. Schaid58, Manuel R. Teixeira59, 60, 61, Paula Paulo61, Andreia Brandão59, 61, Lisa Cannon-Albright62, 63, Craig C Teerlink62, 63, Radka Kaneva64, Chavdar Slavov65, Vanio Mitev64, Hardev Pandha66, Agnieszka Michael66

1The Institute of Cancer Research, London, SM2 5NG, UK

2http://www.icr.ac.uk/our-research/research-divisions/division-of-genetics-and-epidemiology/oncogenetics/research-projects/ukgpcs/ukgpcs-collaborators

3Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, M13 9PL, UK

4Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Strangeways Laboratory, Worts Causeway, Cambridge, CB1 8RN, UK

5Open Targets, Wellcome Sanger Institute, Hinxton, Saffron Walden, CB10 1SA, UK

6Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH 44106-7219, USA

7Seidman Cancer Center, University Hospitals, Cleveland, OH 44106, USA

8Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA

9Center for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA 90015, USA

10Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany

11Saarland Cancer Registry, 66119 Saarbrücken, Germany

12Institute of Biomedicine, Kiinamyllynkatu 10, FI-20014 University of Turku, Finland

13Department of Medical Genetics, Genomics, Laboratory Division, Turku University Hospital, PO Box 52, 20521 Turku, Finland

14Department of Urology, Tampere University Hospital, Tampere, Finland

15Unit of Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland

16Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology, Brisbane QLD 4059, Australia

17Translational Research Institute, Brisbane, Queensland 4102, Australia

18The Kinghorn Cancer Centre, Sydney, Australia

19University of Technology, Sydney

20Cancer Council Queensland, Fortitude Valley, QLD 4006, Australia

21Chris O'Brien Lifehouse (COBLH), Camperdown, Sydney, NSW 2010, Australia

22Garvan Institute of Medical Research, Sydney NSW 2010, Australia

23Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology, Brisbane, 4059, Australia

24Department of Anatomy and Developmental Biology, Biomedicine Discovery Institute, Monash University, Melbourne, Victoria 3800, Australia

25Prostate Cancer Translational Research Program, Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia

26Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide, Adelaide, South Australia, Australia

27Nuffield Department of Surgical Sciences, University of Oxford, Room 6603, Level 6, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK

28University of Cambridge, Department of Oncology, Box 279, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK

29Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Cambridge UK

30Population Health Sciences, Bristol Medical School, University of Bristol, BS8 2PS, UK

31Nuffield Department of Surgical Sciences, University of Oxford, Oxford, OX1 2JD, UK

32Faculty of Medical Science, University of Oxford, John Radcliffe Hospital, Oxford, UK

33National Institute for Health Research (NIHR) Biomedical Research Centre, University of Bristol, Bristol, BS8 1TH, UK

34Medical Research Council (MRC) Integrative Epidemiology Unit, University of Bristol, Bristol, BS8 2BN, UK

35Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark

36Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, 2200 Copenhagen, Denmark

37Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, Copenhagen University Hospital, DK-2730 Herlev, Copenhagen, Denmark

38Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden

39Cancer Epidemiology Division, Cancer Council Victoria, 615 St Kilda Road, Melbourne, VIC 3004, Australia

40Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Grattan Street, Parkville, VIC 3010, Australia

41Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria 3168, Australia

42Department of Clinical Pathology, The Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia.

43Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK

44Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, 2525 West End Avenue, Nashville, TN 37232 USA.

45International Epidemiology Institute, Rockville, MD 20850, USA

46Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109-1024, USA

47Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington 98195, USA

48National Human Genome Research Institute, National Institutes of Health, 50 South Drive, Rm. 5351, Bethesda, MD 20892, USA

49Division of Urologic Surgery, Brigham and Womens Hospital, 75 Francis Street, Boston, MA 02115, USA

50Washington University School of Medicine, 660 S. Euclid Avenue, Campus Box 8242, St. Louis, MO 63110, USA

51Department of Molecular Medicine and Surgery, Karolinska Institutet, and Department of Urology, Karolinska University Hospital, Solna, 171 76 Stockholm, Sweden

52Department of Urology, Karolinska University Hospital, Stockholm, Sweden

53International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland

54Clinical Gerontology Unit, University of Cambridge, Cambridge, CB2 2QQ, UK

55Humangenetik Tuebingen, Paul-Ehrlich-Str 23, D-72076 Tuebingen, Germany

56Department of Urology, University Hospital Ulm, Germany

57Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA

58Division of Biomedical Statistics & Informatics, Mayo Clinic, Rochester, MN 55905, USA

59Department of Genetics, Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal

60Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal

61Cancer Genetics Group, IPO-Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal

62Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine

63George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah, USA

64Molecular Medicine Center, Department of Medical Chemistry and Biochemistry, Medical University of Sofia, Sofia, 2 Zdrave Str., 1431 Sofia, Bulgaria

65Department of Urology and Alexandrovska University Hospital, Medical University of Sofia, 1431 Sofia, Bulgaria

66The University of Surrey, Guildford, Surrey, GU2 7XH, UK

**Funding for the CRUK study and PRACTICAL consortium:**

This work was supported by the Canadian Institutes of Health Research, European Commission's Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative).

**COGS acknowledgement:**

This study would not have been possible without the contributions of the following: Per Hall (COGS); Douglas F. Easton, Paul Pharoah, Kyriaki Michailidou, Manjeet K. Bolla, Qin Wang (BCAC), Andrew Berchuck (OCAC), Rosalind A. Eeles, Douglas F. Easton, Ali Amin Al Olama, Zsofia Kote-Jarai, Sara Benlloch (PRACTICAL), Georgia Chenevix-Trench, Antonis Antoniou, Lesley McGuffog, Fergus Couch and Ken Offit (CIMBA), Joe Dennis, Alison M. Dunning, Andrew Lee, and Ed Dicks, Craig Luccarini and the staff of the Centre for Genetic Epidemiology Laboratory, Javier Benitez, Anna Gonzalez-Neira and the staff of the CNIO genotyping unit, Jacques Simard and Daniel C. Tessier, Francois Bacot, Daniel Vincent, Sylvie LaBoissière and Frederic Robidoux and the staff of the McGill University and Génome Québec Innovation Centre, Stig E. Bojesen, Sune F. Nielsen, Borge G. Nordestgaard, and the staff of the Copenhagen DNA laboratory, and Julie M. Cunningham, Sharon A. Windebank, Christopher A. Hilker, Jeffrey Meyer and the staff of Mayo Clinic Genotyping Core Facility

Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 - the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.

**Additional funding and acknowledgments from studies in PRACTICAL that provided data for this analysis:**

ESTHER

(Epidemiological investigations of the chances of preventing, recognizing early and optimally treating chronic diseases in an elderly population)

The ESTHER study was supported by a grant from the Baden Württemberg Ministry of Science, Research and Arts.

The ESTHER group would like to thank Hartwig Ziegler, Sonja Wolf, Volker Hermann, Heiko Müller, Karina Dieffenbach, Katja Butterbach for valuable contributions to the study.

MEC

(Multiethnic Cohort Study)

The MEC was supported by NIH grants CA063464, CA054281, CA098758, and CA164973.

MOFFITT

(The Moffitt Group)

The Moffitt group was supported by the US National Cancer Institute (R01CA128813, PI: J.Y. Park).

SEARCH

(Study of Epidemiology and Risk factors in Cancer Heredity)

SEARCH is funded by a programme grant from Cancer Research UK [C490/A10124] and supported by the UK National Institute for Health Research Biomedical Research Centre at the University of Cambridge. The University of Cambridge has received salary support in respect of PP from the NHS in the East of England through the Clinical Academic Reserve.

UKGPCS

(U.K. Genetic Prostate Cancer Study)

UKGPCS would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. UKGPCS should also like to acknowledge the NCRN nurses, data managers and Consultants for their work in the UKGPCS.

UKGPCS would like to thank all urologists and other persons involved in the planning, coordination, and data collection of the study. KM and AL were in part supported from the NIHR Manchester Biomedical Research Centre